article thumbnail

FDA Fast Track designation for photodynamic cancer therapy

European Pharmaceutical Review

The drug was evaluated in four Phase II/III clinical trials in patients previously given chemotherapy and/or failed radiation therapy. FTD facilitates drug development and can expedite the review of drugs for serious conditions to help address unmet medical needs.

article thumbnail

Leveraging innate cell engagers for lymphoma treatment

European Pharmaceutical Review

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Oncolytic viruses: past and present

European Pharmaceutical Review

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. After surgery, strategic combinations of radiotherapy, chemotherapy like temozolomide, and other forms of treatment, such as immunotherapy or the use of an electric field cap, are employed.

Immunity 101
article thumbnail

STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug

STAT

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine. Her husband said he had no regrets.

Vaccines 240
article thumbnail

Roche nabs breakthrough tag for TIGIT cancer immunotherapy

pharmaphorum

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression.

article thumbnail

Amivantamab by Johnson & Johnson for Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

article thumbnail

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

While the need for vaccines and drugs appeared more urgent than ever during the pandemic, it is possible that there will be more severe public health crises in years to come. AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them. million direct deaths in 2019 and an additional 4.95